Dianthus Therapeutics Reports $1.2 Million Revenue in Q1 2025, Net Loss of $29.5 Million

Dianthus Therapeutics, Inc. reported its financial results for the first quarter of 2025, revealing total revenues of $1.2 million, a notable increase from $874,000 in the same period last year. The revenue growth was primarily driven by a $1.0 million milestone payment recognized under the Tenacia Agreements, which was partially offset by a decrease in related party license revenue. The company continues to operate at a loss, with a net loss of $29.5 million for the quarter, compared to a net loss of $13.7 million in the first quarter of 2024. This resulted in a net loss per share of $0.82, up from $0.54 in the prior year.

Operating expenses surged to $34.3 million, significantly higher than the $18.7 million reported in the previous year. This increase was largely attributed to a $13.9 million rise in research and development expenses, which totaled $27.0 million for the quarter. The increase in R&D spending reflects heightened activity related to the clinical development of the company’s lead product candidate, DNTH103, which is currently undergoing multiple clinical trials. General and administrative expenses also rose to $7.3 million, up from $5.6 million, driven by increased personnel costs and stock-based compensation.

Dianthus Therapeutics has made strategic advancements, including the completion of a reverse merger with Former Dianthus Therapeutics in September 2023, which has positioned the company for future growth. The company is actively enrolling patients in three mid- to late-stage clinical trials for DNTH103, targeting conditions such as generalized Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy. The company reported a total of 32,159,982 shares of common stock outstanding as of May 7, 2025.

As of March 31, 2025, the company had cash, cash equivalents, and investments totaling $331.5 million, a decrease from $374.0 million at the end of 2024. The company expects its existing cash resources to fund operations into the second half of 2027, although it anticipates needing additional capital to support ongoing clinical trials and operational costs. Dianthus Therapeutics continues to explore various financing options, including equity and debt financing, to ensure sufficient liquidity for its future endeavors. The company remains focused on advancing its product candidates and navigating the complexities of the biotechnology landscape.